We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
IMMU 9.400-11.7%Apr 3 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: TinfoilHat9/17/2019 5:13:37 PM
8 Recommendations

Recommended By

and 3 more members

   of 54970
Been trying to gauge what IMMU will present at SABCS this year given TNBC data has already been published, new trials with PARP inhibitors are still too immature to present. What on earth could move mountains?

Hoping this crack(pipe) team can help me dig up info to corroborate my suspicions, but from the looks of it, we have never yet presented OS data on HR+/HER2- patients from the Phase 1/2 data.

Bardia presented data on 54 patients over a year ago at ASCO highlighting PFS & ORR for IMMU-132 in late stage disease, and at that time 70% of patients were still being monitored.

Can someone help confirm that the OS data has never been published, or am I missing something?

All I can find is they aligned with the FDA on final scope for Ph3, but no publishing of OS data.

From the math of it, this number could be a doozy worthy of SABCS presentation...

Results: Fifty-four pts with HR+/HER2- mBC (all female; median age 54 yrs, range 33-79) were accrued between 2/2015 and 6/2017 (has data been published on OS since 6/2017?)

Take a midpoint of this timeframe, say April 2016, Bardia should have published OS data from this cohort at ASCO theoretically, no?

Keep me on my toes and point out the OS data from this cohort my friends, otherwise, let's see what Santa has in store for us this coming December.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext